The use of BRAF V600E inhibitors in six pLGG patients with the BRAF V600E mutation who experienced tumour progression after being treated with conventional therapy demonstrated a significant cytoreduction of 49% to 80% and prolonged survival in comparison to a 25% tumour reduction after chemotherapy [12]. Here, BRAF is linked to neoplasm.